- Home
- RC vs VIR Comparison
RC vs VIR Comparison
Compare RC & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RC
- VIR
- Stock Information
- Founded
- RC 2007
- VIR 2016
- Country
- RC United States
- VIR United States
- Employees
- RC N/A
- VIR N/A
- Industry
- RC Real Estate Investment Trusts
- VIR Biotechnology: Pharmaceutical Preparations
- Sector
- RC Real Estate
- VIR Health Care
- Exchange
- RC Nasdaq
- VIR Nasdaq
- Market Cap
- RC 755.3M
- VIR 706.4M
- IPO Year
- RC N/A
- VIR 2019
- Fundamental
- Price
- RC $4.29
- VIR $5.42
- Analyst Decision
- RC Hold
- VIR Strong Buy
- Analyst Count
- RC 7
- VIR 8
- Target Price
- RC $7.54
- VIR $30.25
- AVG Volume (30 Days)
- RC 1.9M
- VIR 1.2M
- Earning Date
- RC 08-06-2025
- VIR 07-31-2025
- Dividend Yield
- RC 11.55%
- VIR N/A
- EPS Growth
- RC N/A
- VIR N/A
- EPS
- RC N/A
- VIR N/A
- Revenue
- RC N/A
- VIR $20,861,000.00
- Revenue This Year
- RC N/A
- VIR N/A
- Revenue Next Year
- RC $33.07
- VIR $0.62
- P/E Ratio
- RC N/A
- VIR N/A
- Revenue Growth
- RC N/A
- VIR N/A
- 52 Week Low
- RC $3.93
- VIR $4.32
- 52 Week High
- RC $9.54
- VIR $14.45
- Technical
- Relative Strength Index (RSI)
- RC 41.05
- VIR 50.46
- Support Level
- RC $4.22
- VIR $5.20
- Resistance Level
- RC $4.73
- VIR $6.23
- Average True Range (ATR)
- RC 0.17
- VIR 0.29
- MACD
- RC -0.04
- VIR 0.01
- Stochastic Oscillator
- RC 3.77
- VIR 35.61
About RC Ready Capital Corproation
Ready Capital Corp is a real estate finance company. It acquires, manages, originates, and finances small-balance commercial loans to purchase small multi-family, office, retail, mixed-use, or warehouse properties. The company's segments consist of LMM Commercial Real Estate and Small Business Lending. It generates the majority of its revenue from LMM Commercial Real Estate.
About VIR Vir Biotechnology Inc.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.